Here are the most active stocks on Monday mid-morning on the TSX and TSX Venture Exchange.
On Monday, the top TSX mover was
TORC Oil and Gas Ltd. (
TSX: T.TOG,
Stock Forum). It rose 1.8% and was trading at $1.70 on volume of 6.2 million shares.
On August 13, the exploration, development and production company reported a net loss of $3.4 million or $0.02 per a share and $4.5 million or $0.02 per a share for the three and six months ended June 30, 2013 respectively.
B2Gold Corp. (
TSX: T.BTO,
Stock Forum) was the second most active stock on the TSX. The stock was down 7.7% and trading at $3.14 on volume of 2.7 million.
On August 13, the gold producer announced net earnings of $33.1 million or $0.05 per share for its second quarter ended June 30, 2013.
Intertainment Media Inc. (
TSX: V.INT,
Stock Forum) was the volume leader on the TSX Venture Exchange. It soared 100% and was trading at $0.11 on volume of 11.7 million.
Today, the marketing services company reported that its subsidiary, Ortsbo, Inc. announced a strategic partnership with TELUS International to support global customer care. TELUS International is a leading customer care outsourcing organization with almost 16,000 team members around the world providing Business Process Outsourcing (BPO) and contact center solutions to some of the largest global brands in the high tech, financial services, telecommunications, utility, and consumer goods industries.
The second most active stock on the TSX Venture was
Sirona Biochem Corp. (
TSX: V.SBM,
Stock Forum) It rose 29% and was trading at $0.155 after five million shares changed hands.
Today, the biotech company announced the signing of a letter of intent whereby Sirona Biochem will provide an exclusive license to Wanbang Pharma to develop and commercialize Sirona's SGLT2 Inhibitor in the People's Republic of China (PRC). In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC. Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology.